An investigation for investors in NASDAQ:MRTX shares was announced concerning potential securities laws violations in connection certain financial statements.
Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Mirati Therapeutics, Inc. (NASDAQ:MRTX) concerning whether a series of statements regarding Mirati Therapeutics’ business, its prospects and its operations were materially false and misleading at the time they were made.
On June 5, 2016, Mirati Therapeutics, Inc. provided an update on three current ongoing clinical programs in patients with non-small cell lung cancer (NSCLC) and other solid tumors. Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) declined from as high as $19.25 per share on June 3, 2016, to as low as $5.48 per share on June 27, 2016.
On June 28, 2016, NASDAQ: MRTX shares closed at $5.57 per share.
Those who purchased NASDAQ:MRTX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego